Help
RSS
API
Feed
Maltego
Contact
Domain > ra-option.com
×
Welcome!
Right click nodes and scroll the mouse to navigate the graph.
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2016-02-10
54.231.184.99
(
ClassC
)
2019-06-09
52.218.218.186
(
ClassC
)
2024-09-06
52.218.218.162
(
ClassC
)
2024-10-02
52.92.243.179
(
ClassC
)
Port 80
HTTP/1.1 200 OKx-amz-id-2: ARCFhyNHtssO5G3XftfF8KC9qUGLdebajubMHXvykIBkAa3B1RIQk/ysIdKMH6o2NBZBnGREzQYx-amz-request-id: M292BBDVMD0DJPBBDate: Fri, 06 Sep 2024 23:51:07 GMTLast-Modified: Fri, 28 Aug 20 !DOCTYPE html PUBLIC -//W3C//DTD XHTML 1.0 Transitional//EN http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd>!--if lt IE 7 > html classie6> !endif-->!--if IE 7 > html classie7> !endif-->!--if IE 8 > html classie8> !endif-->!--if IE 9 > html classie9> !endif-->!--if (gt IE 9)|!(IE)>!--> html class> !--!endif-->head> title>An RA Treatment Option/title> meta charsetUTF-8> meta http-equivX-UA-Compatible contentIEedge,chrome1 /> meta namedescription contentLearn about additional RA treatment options available to you. Find Out Here.> !-- link relshortcut icon typeimage/x-icon hrefhttp://cdn.rasuvo.com/assets/images/favicon.ico> --> link relstylesheet typetext/css hrefmain.css>/head>body> img srcimg/bg-sm.jpg styledisplay:none; altMedac background mobile /> img srcimg/bg.jpg styledisplay:none; altMedac background desktop /> div idvw-test>/div> section classmain-container>/section> div classcontent> div classcontent-inner> div classlist-content> h1>Rheumatoid arthritis (RA) is a multisystem autoimmune disordersup>1,2/sup>/h1> ul> li>RA is characterized by chronic, destructive inflammation of the synovium/li> li>RA can lead to bone erosion and weakened muscles and tendons/li> li>RA affects approximately 1.3 million adults in the United States/li> /ul> h1>Goals of treating RAsup>3,4/sup>/h1> ul> li>Reach a point of low disease activity/li> li>If possible, achieve clinical remission of disease/li> /ul> h1>DMARDs and Methotrexatesup>5/sup>/h1> ul> li>Disease-modifying anti-rheumatic drugs, (DMARDs), are used to inhibit radiographic progression and help reach the goals of treating RA /li> li>The DMARD methotrexate (MTX) can be administered orally or parenterally (most often using the subcutaneous SC route)/li> /ul> h1>Optimizing Methotrexate Treatment in RA/h1> ul> li>28% of patients with early, poor-prognosis RA achieve the goal of low disease activity with MTX monotherapy6 /li> li>The use of SC MTX may help patients stay on MTX treatment longer, and provide
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]